Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963627 | 0.85 | TACR2 (0.43) | TACR2 | |
| SCHEMBL6440565 | 0.82 | MMP1 (0.43) | TACR2MMP1 | |
| SCHEMBL8051789 | 0.82 | MMP1 (0.43) | TACR2MMP1 | |
| SCHEMBL5963437 | 0.82 | ALDH1A1 (0.38) | MMP1 | |
| SCHEMBL5963481 | 0.81 | MAPT (0.45) | — | |
| SCHEMBL5963129 | 0.79 | TACR2 (0.50) | TACR2 | |
| SCHEMBL6828517 | 0.76 | ACACB (0.39) | TACR2 | |
| SCHEMBL8067899 | 0.76 | MMP1 (0.41) | TACR2MMP1 | |
| SCHEMBL8063643 | 0.74 | HTRA1 (0.46) | MMP1 | |
| SCHEMBL8061343 | 0.74 | ECE1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | FINK CYNTHIA A | 2006-08-31 | — | — | US | disclosed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | disclosed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | ECE1, ECE2, AGTR1 | TACR2 183/4885MMP1 1603/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | TACR2 622/4885MMP1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.